Morgan Hebert
Family · Ville Platte, LANPI 1669193298
Payments from drug & device makers
Across 384 payments — averaging $16.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$697
- Pfizer$454
- Sumitomo Pharma America, Inc.$436
- GSK$420
- Novo Nordisk$393
- plus $2K from 30 others
What the payments were for
- Food & beverage$6,194100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 84 | $1,538 |
| AstraZeneca | 35 | $697 |
| Pfizer | 44 | $454 |
| Sumitomo Pharma America, Inc. | 36 | $436 |
| GSK | 28 | $420 |
| Novo Nordisk | 30 | $393 |
| Merck | 17 | $254 |
| Lilly USA, LLC | 10 | $180 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $162 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $160 |
| Phathom Pharmaceuticals, Inc. | 7 | $123 |
| Otsuka America Pharmaceutical, Inc. | 7 | $115 |
| Ardelyx, Inc. | 6 | $109 |
| Exact Sciences | 7 | $108 |
| Boehringer Ingelheim | 6 | $97 |
| Astellas Pharma US Inc | 5 | $90 |
| Viatris Specialty LLC | 5 | $79 |
| Bayer | 5 | $79 |
| Lundbeck LLC | 3 | $65 |
| Kestra Medical Technology Services, Inc. | 3 | $63 |
| Idorsia Pharmaceuticals US Inc | 4 | $63 |
| Alkermes, Inc. | 3 | $61 |
| Novartis | 4 | $60 |
| Axsome Therapeutics, Inc. | 2 | $59 |
| Mylan Specialty L.p. | 3 | $58 |
| Sanofi-aventis U.S. LLC | 3 | $57 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $47 |
| Valinor Pharma, LLC | 2 | $37 |
| Verona Pharma, Inc. | 1 | $24 |
| Paratek Pharmaceuticals, Inc. | 1 | $19 |
| Fresenius USA Marketing, Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $15 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
| Ironwood Pharmaceuticals, Inc | 1 | $14 |
| Amgen | 1 | $13 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$129
How this compares
$6,194 in reported general payments places this provider in the 90th percentile of 3,610 family providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 174 | $169,668 |
| JardianceEmpagliflozin | 168 | $125,235 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 118 | $75,042 |
| LinzessLinaclotide | 118 | $66,873 |
| VraylarCariprazine Hcl | 40 | $62,301 |
| FarxigaDapagliflozin Propanediol | 89 | $54,318 |
| MounjaroTirzepatide | 48 | $51,258 |
| TrulicityDulaglutide | 36 | $44,902 |
| EliquisApixaban | 67 | $40,224 |
| JanuviaSitagliptin Phosphate | 72 | $39,656 |
| RybelsusSemaglutide | 41 | $39,275 |
| XareltoRivaroxaban | 56 | $37,148 |
| UbrelvyUbrogepant | 25 | $31,675 |
| EntrestoSacubitril/Valsartan | 36 | $28,975 |
| GemtesaVibegron | 47 | $28,716 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $393 | $208,943215 claims |
| AbbVieLinzess, Vraylar, Ubrelvy | $1,538 | $160,849183 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Stiolto Respimat | $97 | $150,196207 claims |
| Lilly USA, LLCMounjaro, Trulicity | $180 | $96,16084 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $697 | $84,302148 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $420 | $82,353134 claims |
| MerckJanuvia, Janumet Xr | $254 | $46,57684 claims |
| PfizerEliquis | $454 | $40,22467 claims |
| Johnson & JohnsonXarelto | $15 | $37,14856 claims |
| NovartisEntresto | $60 | $28,97536 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $436 | $28,71647 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $160 | $25,68845 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,610 family providers in Louisiana.
Other family in Ville Platte
- Brittany MillerVille Platte$158K
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.